InnoCare reveals groundbreaking orelabrutinib data at ASH conference

In Beijing, on December 9, 2024, InnoCare shared new findings regarding their drug orelabrutinib during the ongoing 66th American Society of Hematology (ASH) Annual Meeting. The presented data highlighted orelabrutinib's promising efficacy and safety in patients with prior BTK inhibitor intolerance and indolent Non-Hodgkin Lymphoma (iNHL). With a median follow-up of 6.8 months, significant metrics were noted, including peripheral blood undetectable minimal residual disease (uMRD) rates of 95% and bone marrow uMRD rates of 86% after cycle 6. Patients demonstrated a 59% rate of complete response (CR) or CR with incomplete hematologic recovery (CRi). Additionally, a phase II clinical trial evaluated the combination of orelabrutinib and rituximab for relapsed/refractory Marginal Zone Lymphoma (MZL), showing effective results with tolerable safety for maintenance therapy. Out of those who achieved a complete response, none relapsed while on orelabrutinib maintenance therapy. The findings suggest the potential of this combination in managing MZL. Further data indicated the efficacy of orelabrutinib with or without rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients after BTK inhibitor therapy. Here, 66.7% achieved undetectable peripheral blood MRD, supporting the drug's potential as a treatment option in this context. Another aspect of present research highlighted the effectiveness of the ORM regimen (oral orelabrutinib, rituximab, and methotrexate) for primary central nervous system lymphoma (PCNSL), showcasing an overall response rate of 96.15% and a complete response rate of 92.30% after four cycles. These advancements illustrate the expanding role of orelabrutinib as a therapeutic option and the ongoing exploration of its safety and efficacy across various lymphoid malignancies.